Form 8-K · Current report
Bunge Global 8-K, filed Jul 29, 2026
- Filed
- CIK
- 0001996862
- Accession no.
- 0001628280-26-050334
Summary
Bunge Global SA reported second-quarter 2026 GAAP diluted EPS of $3.47, up from $2.61 a year earlier, and adjusted diluted EPS of $2.00, up from $1.31, while raising its full-year adjusted EPS outlook to $9.25-$9.75 from $9.00-$9.50. Bunge also said it repurchased about $250 million of shares, completing a $2 billion program tied to the Viterra transaction.
Key points
- Bunge reported second-quarter 2026 GAAP diluted EPS of $3.47, compared with $2.61 a year earlier, and adjusted diluted EPS of $2.00, compared with $1.31.
- Bunge raised its full-year adjusted EPS outlook range to $9.25 to $9.75 from $9.00 to $9.50.
- Bunge repurchased about $250 million of shares, completing the $2 billion program related to the Viterra transaction.
- Higher results were primarily driven by strong performances in Soybean and Softseed Processing and Refining segments.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On July 29, 2026, Bunge Global SA ("Bunge") issued a press release announcing its financial results for the three and six months ended June 30, 2026. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. In accordance with general instruction B.2 of Form 8-K, the information in this Item 2.02, including exhibits, is furnished pursuant to Items 2.02 and 9.01 and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Item 9.01 Financial Statements and Exhibits (d): Exhibits. Exhibit No. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.